Sifeng Qu

842 total citations · 1 hit paper
21 papers, 514 citations indexed

About

Sifeng Qu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Sifeng Qu has authored 21 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Sifeng Qu's work include Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Sifeng Qu is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Sifeng Qu collaborates with scholars based in China, Canada and United States. Sifeng Qu's co-authors include Xiaorong Yang, Xia Sun, Hao Wang, Hui Chen, Fan Yi, Peter W. Gout, Yuzhuo Wang, Pier‐Luc Clermont, Cheryl D. Helgason and Wenlin Jiao and has published in prestigious journals such as Cancer Research, Scientific Reports and British Journal of Cancer.

In The Last Decade

Sifeng Qu

18 papers receiving 505 citations

Hit Papers

Disease burden and long-term trends of urinary tract infe... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Disease burden and long-term trends of urinary tract infections: A worldwide report
    2022 149 citations Xiaorong Yang, Hui Chen et al. Frontiers in Public Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sifeng Qu China 10 220 137 120 85 61 21 514
Masato Watanabe Japan 15 200 0.9× 139 1.0× 74 0.6× 35 0.4× 80 1.3× 76 678
Sarinya Kongpetch Thailand 17 404 1.8× 88 0.6× 38 0.3× 167 2.0× 45 0.7× 40 760
Wenxia Yao China 14 246 1.1× 56 0.4× 82 0.7× 116 1.4× 12 0.2× 27 496
Guangmin Xi China 13 656 3.0× 207 1.5× 170 1.4× 189 2.2× 52 0.9× 20 893
Ruichuang Yang China 13 275 1.3× 40 0.3× 66 0.6× 109 1.3× 23 0.4× 21 586
Shuli Yang China 14 277 1.3× 74 0.5× 40 0.3× 162 1.9× 23 0.4× 34 616
Hye‐Lin Ha United States 14 249 1.1× 24 0.2× 137 1.1× 68 0.8× 20 0.3× 16 698
Liviuţa Budişan Romania 13 355 1.6× 76 0.6× 69 0.6× 243 2.9× 19 0.3× 51 674
Jinsen Lu China 13 217 1.0× 68 0.5× 96 0.8× 77 0.9× 11 0.2× 18 445

Countries citing papers authored by Sifeng Qu

Since Specialization
Citations

This map shows the geographic impact of Sifeng Qu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sifeng Qu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sifeng Qu more than expected).

Fields of papers citing papers by Sifeng Qu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sifeng Qu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sifeng Qu. The network helps show where Sifeng Qu may publish in the future.

Co-authorship network of co-authors of Sifeng Qu

This figure shows the co-authorship network connecting the top 25 collaborators of Sifeng Qu. A scholar is included among the top collaborators of Sifeng Qu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sifeng Qu. Sifeng Qu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Xia, et al.. (2025). Identification of novel gene-based risk score for prognosis in prostate cancer. Scientific Reports. 15(1). 22128–22128.
2.
Zhou, Bin, Pei-Xin Li, Xiaoyi Zhang, et al.. (2024). Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy. Annals of Medicine. 57(1). 2442067–2442067. 1 indexed citations
3.
Sun, Xia, et al.. (2023). Overexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance. Frontiers in Genetics. 14. 1108004–1108004. 4 indexed citations
4.
Qu, Sifeng, et al.. (2022). An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report. Medicine. 101(52). e32529–e32529.
5.
Wang, Jian, Jianfeng Cui, Sifeng Qu, et al.. (2022). Arterioureteral fistula after radical cystectomy and ureterocutaneostomy: two case reports and a systematic literature review. BMC Urology. 22(1). 117–117. 1 indexed citations
6.
7.
Qu, Sifeng, et al.. (2022). Comparison of a Personalized Prostate Biopsy Pattern With Traditional Transrectal Prostate Biopsy: Different Cancer Detection Rate. Frontiers in Cell and Developmental Biology. 10. 851359–851359. 1 indexed citations
8.
Cui, Jianfeng, et al.. (2022). Construction and Comparison of Different Models in Detecting Prostate Cancer and Clinically Significant Prostate Cancer. Frontiers in Oncology. 12. 911725–911725. 7 indexed citations
9.
Yang, Xiaorong, et al.. (2022). Disease burden and long-term trends of urinary tract infections: A worldwide report. Frontiers in Public Health. 10. 888205–888205. 149 indexed citations breakdown →
10.
11.
Qin, Jing, Sifeng Qu, Kongkai Zhu, et al.. (2021). Rational design and synthesis of 6-aryl-6H-benzo[c]chromenes as non-steroidal progesterone receptor antagonists for use against cancers. Bioorganic & Medicinal Chemistry. 32. 116003–116003. 6 indexed citations
12.
He, Haiqing, Jun Hao, Xin Dong, et al.. (2021). ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development. Prostate Cancer and Prostatic Diseases. 24(3). 775–785.
13.
Zhang, Wenbo, Feifei Sun, Jing Hu, et al.. (2020). KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. Cancer Research. 81(4). 1026–1039. 57 indexed citations
14.
Ci, Xinpei, Jun Hao, Xin Dong, et al.. (2018). Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research. 78(10). 2691–2704. 55 indexed citations
15.
16.
Qu, Sifeng, Xinpei Ci, Hui Xue, et al.. (2018). Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. British Journal of Cancer. 118(6). 802–812. 14 indexed citations
17.
Lin, Dong, Susan Ettinger, Sifeng Qu, et al.. (2017). Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. Oncotarget. 8(16). 25928–25941. 18 indexed citations
18.
Sun, Xia, Pier‐Luc Clermont, Wenlin Jiao, et al.. (2016). Elevated expression of the centromere protein‐A(CENP‐A)‐encoding gene as a prognostic and predictive biomarker in human cancers. International Journal of Cancer. 139(4). 899–907. 83 indexed citations
19.
Qu, Sifeng, Kendric Wang, Hui Xue, et al.. (2013). Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient‐derived, advanced prostate cancer tissue xenograft model. Molecular Oncology. 8(2). 311–322. 28 indexed citations
20.
Sun, Xia, Xinbing Wei, Sifeng Qu, Yunxue Zhao, & Xiumei Zhang. (2010). Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia–reperfusion in rats. Bioorganic & Medicinal Chemistry Letters. 20(14). 4120–4124. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masato Watanabe Breakdown of academic impact, for papers by Sarinya Kongpetch Breakdown of academic impact, for papers by Wenxia Yao Breakdown of academic impact, for papers by Guangmin Xi Breakdown of academic impact, for papers by Ruichuang Yang Breakdown of academic impact, for papers by Shuli Yang Breakdown of academic impact, for papers by Hye‐Lin Ha Breakdown of academic impact, for papers by Liviuţa Budişan Breakdown of academic impact, for papers by Jinsen Lu
Rankless by CCL
2026